| Literature DB >> 36035953 |
Guangqiang Wang1, Lin Zhong1, Hongxia Chu1, Chunxiao Wang1, Xuefeng Zhu1.
Abstract
Background: The short-coupled variant of torsade de pointes (scTdP) is characterized by a particular electrocardiogram (ECG) pattern that shows a short-coupling interval of the initial Tdp beat and that can degenerate into ventricular fibrillation without the presence of structural heart disease. However, its etiology, epidemiology, clinical characteristics, underlying mechanism, treatment, and prognosis remain unclear. This study aimed to systematically review case reports and series of scTdP to synthesize existing data on the demography, clinical characteristics, ECG features, management, and outcomes.Entities:
Keywords: QRS duration of ventricular extrasystole; first-coupling interval; implantable cardioverter defibrillator; short-coupled variant of torsade de pointes; systematic review
Year: 2022 PMID: 36035953 PMCID: PMC9411750 DOI: 10.3389/fcvm.2022.922525
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1Flow diagram.
Characteristics of the case reports.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leenhardt ( | France | Case report | 21 | 33 ± 11 | 10 (48) | 1 (5) | 0 (0) | 5 (24) | 3 (18) | 20 (95) | 1 (5) | 9 (64) | 12 (86) | NA | Normal | 297 ± 41 | 2 (14) | NA | 4 (19) | 9 (43) | 52 ± 51 | 15 (71) |
| Ruan and Wang ( | China | Case report | 3 | 36 ± 5 | 2 (67) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (100) | 0 (0) | NA | 2 (67) | NA | Normal | 377 ± 25 | NA | NA | 0 (0) | 1 (33) | 7 ± 6 | 2 (67) |
| Shiga et al. ( | Japan | Case report | 1 | 41 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | NA | 0 (0) | NA | Normal | 240 | 1 (100) | 156 | 1 (100) | 1 (100) | 60 | 1 (100) |
| Haïssaguerre et al. ( | France, Japan, Czech Republic, | Case report | 27 | 41 ± 14 | 14 (52) | 0 (0) | 0 (0) | 6 (22) | 0 (0) | 17 (63) | 0 (0) | 27 (100) | 27 (100) | NA | Normal | 297 ± 41 | 10 (37) | 129 ± 18 | 23 (85) | 3 (11) | 24 ± 28 | 27 (100) |
| Takeuchi et al. ( | Japan | Case report | 1 | 51 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | NA | 1 (100) | NA | Normal | 280 | 0 (0) | 120 | 1 (100) | 0 (0) | 6 | 1 (100) |
| Noda et al. ( | Japan | Case control study | 16 | 39 ± 10 | 9 (56) | 0 (0) | 0 (0) | 1 (6) | 0 (0) | 11 (69) | 0 (0) | 16 (100) | 16 (100) | NA | Normal | 403 ± 21 | 3 (19) | 148 ± 8 | 1 (6) | 0 (0) | 54 ± 39 | 16 (100) |
| Viskin et al. ( | Israel | Case report | 3 | 48 ± 11 | 3 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (33) | 0 (0) | 3 (100) | 3 (100) | NA | Normal | 350 ± 20 | 0 (0) | 149 ± 7 | 2 (67) | 0 (0) | 42 ± 48 | 3 (100) |
| Yamazaki et al. ( | Japan | Case report | 1 | 21 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 1 (100) | NA | Normal | 300 | 0 (0) | 120 | 0 (0) | 0 (0) | 36 | 1 (100) |
| Bogaard et al. ( | Netherlands | Case report | 1 | 36 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | NA | 1 (100) | NA | Normal | 240 | 0 (0) | 120 | 1 (100) | 0 (0) | 6 | 1 (100) |
| Chiladakis et al. ( | Greece | Case report | 1 | 50 | 1 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | NA | 1 (100) | NA | Normal | 290 | 0 (0) | 120 | 1 (100) | 0 (0) | 3 | 1 (100) |
| Van den branden et al. ( | Netherlands | Case report | 1 | 51 | 0 (0) | 1 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 1 (100) | NA | NA | Normal | 240 | NA | 160 | 1 (100) | 0 (0) | 12 | 1 (100) |
| Chokr et al. | Brazil | Case report | 4 | 32 ± 16 | 4 (100) | 0 (0) | 0 (0) | 0 (0) | 3 (75) | 3 (75) | 0 (0) | 2 (50) | 2 (50) | NA | Normal | 300 ± 43 | 0 (0) | 155 ± 13 | 3 (75) | 1 (25) | 71 ± 90 | 4 (100) |
| Hayama et al. ( | Japan | Case report | 1 | 38 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | NA | 1 (100) | (-) | Normal | 280 | 0 (0) | 142 | 1 (100) | 0 (0) | 15 | 1 (100) |
| Jastrzebski et al. ( | Kraków | Case report | 5 | 43 ± 19 | 4 (80) | 1 (20) | 1 (20) | 0 (0) | 0 (0) | 5 (100) | 0 (0) | 1 (20) | NA | NA | Normal | 303 ± 38 | NA | 130 ± 17 | 5 (100) | 3 (60) | 51 ± 29 | 5 (100) |
| Kondo et al. ( | Japan | Case report | 1 | 19 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | NA | 1 (100) | (-) | Normal | 300 | 0 (0) | 128 | 1 (100) | 0 (0) | 8 | 1 (100) |
| Godinho et al. ( | Portugal | Case report | 1 | 49 | 1 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | NA | 1 (100) | NA | Normal | 280 | 0 (0) | 160 | 1 (100) | 0 (0) | 6 | 1 (100) |
| Fujii et al. ( | Japan | Case report | 6 | 38 ± 9 | 3 (50) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 6 (100) | 0 (0) | 1 (17) | 3 (50) | (+) | Normal | 426 ± 21 | 3 (50) | 138 ± 16 | 6 (100) | 3 (50) | 62 ± 25 | 6 (100) |
| Kimura et al. ( | Japan | Case report | 1 | 40 | 1 (100) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 1 (100) | 0 (0) | 0 (0) | 1 (100) | (+) | Normal | 280 | 0 (0) | 110 | 1 (100) | 0 (0) | NA | 1 (100) |
| Kajiyama et al. ( | Japan | Case report | 1 | 40 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | NA | 1 (100) | (+) | Normal | 250 | 0 (0) | 130 | 1 (100) | 1 (100) | 24 | 1 (100) |
| Sonoda et al. ( | Japan | Case report | 1 | 38 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | NA | 1 (100) | (+) | Normal | 280 | 0 (0) | 120 | 1 (100) | 0 (0) | NA | 1 (100) |
| Steinfurt et al. ( | Germany, USA and Netherlands | Case report | 5 | 37 ± 13 | 2 (40) | 0 (0) | 0 (0) | 1 (20) | 0 (0) | 1 (20) | 4 (80) | NA | 5 (100) | NA | Normal | 262 ± 20 | 0 (0) | 126 ± 5 | 5 (100) | 0 (0) | 32 ± 37 | 5 (100) |
| Touat-Hamici et al. ( | France | Case report | 1 | 35 | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 1 (100) | 0 (0) | 1 (100) | NA | (+) | Normal | 280 | NA | 120 | 0 (0) | 1 (100) | 72 | 0 (0) |
| Total | - | - | 103 | 38 ± 12 | 54 (52) | 3 (3) | 1 (1) | 15 (15) | 6 (6) | 78 (76) | 6 (6) | 62 (78) | 80 (91) | – | Normal | 302 ± 62 | 19 (22) | 135 ± 17 | 60 (58) | 23 (22) | 40 ± 41 | 95 (92) |
ICD, Implantable cardioverter defibrillator; SD, Standard deviation; NA, Not applicable.
Critical appraisal checklist for case reports included in this review.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Were patient's demographic characteristics clearly described? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 2. Was the patient's history clearly described and presented as a timeline? | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 3. Was the current clinical condition of the patient on presentation clearly described? | No | No | Yes | No | Yes | No | No | No | Yes | Yes | No | No | Yes | No | Yes | Yes | No | Yes | Yes | Yes | No | No |
| 4. Were diagnostic tests or assessment methods and the results clearly described? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 5. Was the intervention(s) or treatment procedure(s) clearly described? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 6. Was the post-intervention clinical condition clearly described? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 7. Were adverse events (harms) or unanticipated events identified and described? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 8. Does the case report provide take away lessions? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Overall appraisal: include, exclude, and seek further information | Include | Include | Include | Include | Include | Include | Include | Include | Include | Include | Include | Include | Include | Include | Include | Include | Include | Include | Include | Include | Include | Include |
Figure 2Distribution of the different origins of short-coupled variant of torsade de pointes (scTdP).
Clinical characteristics of the different ventricular extrasystole's origins.
|
|
|
|
|
|---|---|---|---|
| Age (y, mean ± SD) | 38 ± 11 | 38 ± 12 | 0.855 |
| Male ( | 9 (43) | 24 (52) | 0.479 |
| No structural heart disease ( | 25 (100) | 68 (99) | 1 |
| Family history of cardiac disease or sudden death ( | 1 (5) | 7 (15) | 0.413 |
| Emotion and exercise ( | 1 (4) | 4 (6) | 0.754 |
| First coupling interval (ms, mean ± SD) | 380 ± 70 | 274 ± 28 | <0.001 |
| QRS duration of ventricular extrasystole (ms, mean ± SD) | 147 ± 8 | 131 ± 17 | <0.001 |
| VF ( | 12 (48) | 54 (78) | 0.005 |
| Electrical storm ( | 0 (0) | 6 (9) | 0.295 |
| RFCA Monotherapy/Combination therapy ( | 21 (84) | 36 (52) | 0.005 |
| ICD Monotherapy/Combination therapy ( | 3 (12) | 55 (80) | <0.001 |
| Only medicines treatment ( | 2 (8) | 12 (17) | 0.422 |
| Death ( | 1 (4) | 5 (7) | 0.888 |
RVOT, Right ventricular outflow tract; SD, Standard deviation; VF, Ventricular fibrillation; RFCA, Radiofrequency catheter ablation; ICD, Implantable cardioverter defibrillator.
Figure 3ROC analyses of the optimal cutoff values of the short-coupled interval triggering torsade de pointes (TdP) (A) and QRS duration of ventricular extrasystole (VE) (B) for predicting the right ventricular outflow tract (RVOT) origin.
Figure 4Comparison of Kaplan-Meier survival curves in short-coupled variant of torsade de pointes (scTdP) patients with different treatments. (A) implantable cardioverter defibrillator (ICD) vs. medication (P < 0.001); (B) radiofrequency catheter ablation (RFCA) vs. medication (P = 0.006); (C) ICD vs. non-ICD (P = 0.001).
Figure 5Application distribution (A) and constitution (B) of different treatment strategies, including radiofrequency catheter ablation (RFCA), implantable cardioverter defibrillator (ICD), and drugs, in patients with short-coupled variant of torsade de pointes (scTdP).